Pål Rongved (CSO) and Ragnar Hovland (CTO) presented Adjutec at European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Lisbon 23-26th April. The meeting confirmed the unmet medical need for new technology including enzyme inhibitors. The lack of new effective products results in the use of previously abandoned antibiotics, including polymyxins that results in increasing patient morbidity and mortality.
Rebekka Rolfsnes was recently employed by Adjutec for three years to do her PhD program at University of Oslo. Rebekka is a molecular biologist by training and will do her PhD studying mechanism-of-actions of Adjutec’s new broad-spectrum enzyme inhibitor APC247. She recently presented a poster about Adjutec R&D pipeline when attending an educational meeting in Sweden.
AdjuTec will be present at the World Anti-Microbial Resistance Congress 2022 taking place in Washington DC 7-8th September. This is an AMR conference with focus on partnering and networking for innovative biotech’s and international pharma. After the pandemic, it is particular important to meet with potential partners.
“Adjutec plans for R&D and distribution partnering after initial value creation for early investors. Adjutec needs to be on the radar of investors and international pharma over time to show that we are able to deliver forefront innovations. These meetings are excellent platform to connect to the antimicrobial community” says CEO Bjørn Klem.
About antimicrobial resistance (AMR) – https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
AMR is a global health and development threat. It requires urgent multi-sectoral action in order to achieve the Sustainable Development Goals (SDGs). WHO has declared that AMR is one of the top 10 global public health threats facing humanity. Misuse of antimicrobials are the main drivers in the development of drug-resistant pathogens. Lack of clean water and sanitation and inadequate infection prevention and control promotes the spread of microbes, some of which can be resistant to antimicrobial treatment. The cost of AMR to the economy is significant. In addition to death and disability, prolonged illness results in longer hospital stays at intensive care units and isolate wards. In addition, there is a need for more expensive medicines and financial challenges for those impacted. Without effective antimicrobials, the success of modern medicine in treating and preventing infections during major surgery and cancer chemotherapy, can be jeopardized.
About AdjuTec Pharma
AdjuTec Pharma is a Company that is dedicated to developing and providing novel antibiotic resistance breakers to the global market. The Company technology offers a unique mechanism of action that inactivates bacterial defense enzymes and restores bacterial sensitivity to antibiotics. The Company lead product is APC148, a selective zinc chelator targeting bacteria metallo-ß-lactamase (MBL) enzymes. The technology is developed by Professor Pål Rongved and his group at Department of Pharmacy, University of Oslo. The Company is located at Oslo Cancer Cluster Innovation Park next to the Radium Hospital, Oslo.
For more information, please visit www.adjutecpharma.com
Please contact: info@adjutecpharma.com